Novartis has eyes for Alcon

Share this article:
Novartis shelled out $10.4 billion to Nestle for a 25% stake in eye care company Alcon.

The drugmaker holds exclusive rights to acquire Nestle's remaining 52% share in the company under an option commencing January 1, 2010, and running through July 31, 2011.

The acquisition would broaden Novartis' consumer ophthalmic franchise, a useful hedge at a difficult time for pharma. Fort Worth, TX-based Alcon's products include: the Opti-Free contact lens care franchise, along with Systane lubricant drops and I-Caps eye vitamin drops; surgical products including AcrySof lenses; eye allergy drop Patanol and ear infection treatment Ciprodex. Novartis ophthalmic products include its CIBA Vision contact lens line and, outside of the US, wet AMD treatment Lucentis.
 
As part of the deal, Novartis chairman and CEO Daniel Vasella joins Alcon's board of directors, along with Nestle EVP/CFO James Singh.
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.